Atlas Trials

KalVista Pharmaceuticals, Ltd.

15 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch KalVista Pharmaceuticals, Ltd.

RecordFirmDate
Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL) (NCT07654829)KalVista Pharmaceuticals, Ltd.2026-07-31
A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks (NCT07009262)KalVista Pharmaceuticals, Ltd.2025-04-21
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II (NCT06467084)KalVista Pharmaceuticals, Ltd.2024-08-01
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) (NCT05505916)KalVista Pharmaceuticals, Ltd.2022-10-24
A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE) (NCT05259917)KalVista Pharmaceuticals, Ltd.2022-02-22
A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II (NCT05055258)KalVista Pharmaceuticals, Ltd.2021-11-18
Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations (NCT05118958)KalVista Pharmaceuticals, Ltd.2020-05-19
A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II (NCT04208412)KalVista Pharmaceuticals, Ltd.2019-07-02
A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers (NCT05178355)KalVista Pharmaceuticals, Ltd.2019-02-12
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME) (NCT03466099)KalVista Pharmaceuticals, Ltd.2018-02-16
A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers (NCT04349800)KalVista Pharmaceuticals, Ltd.2018-01-04

Track KalVista Pharmaceuticals, Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.